Image of Martin Braddock

Martin Braddock

Tralokinumab Global Development Team Science Lead, Drug Development @ AstraZeneca

Tralokinumab Global Development Team, Science Lead Drug Development at AstraZeneca

Nottingham, Nottinghamshire, United Kingdom

Ranked #1,373 out of 27,460 for Tralokinumab Global Development Team Science Lead, Drug Development in United States

Section title

Martin Braddock's Email Addresses & Phone Numbers

Martin Braddock's Work Experience

AstraZeneca

Tralokinumab Global Development Team Science Lead, Drug Development

November 2013 to Present

AstraZeneca

Senior Principal Scientist Late Stage Development Projects

September 2013 to Present

AstraZeneca

Senior Principal Scientist

June 2004 to Present

Martin Braddock's Education

MRC Radiobiology Unit Harwell, Holt Radium Institute and University of Salford

Ph.D Radiation Biology

1981 to 1984

University of Salford

B.Sc. Biochemistry

1978 to 1981

Richard Hale School

1971 to 1978

Martin Braddock's Professional Skills Radar Chart

Based on our findings, Martin Braddock is ...

Adventurous
Kind
Firm

What's on Martin Braddock's mind?

Based on our findings, Martin Braddock is ...

21% Left Brained
79% Right Brained

Martin Braddock's Estimated Salary Range

About Martin Braddock's Current Company

AstraZeneca

Tralokinumab is an IL-13 monoclonal antibody in phase III clinical development for patients with severe asthma. My role is to build and strengthen the science throughout the phase III clinical programme, aligned to the target product profile to support both the regulatory submission and the developing brand within the portfolio of late stage development candidates.

Frequently Asked Questions about Martin Braddock

What company does Martin Braddock work for?

Martin Braddock works for AstraZeneca


What is Martin Braddock's role at AstraZeneca?

Martin Braddock is Tralokinumab Global Development Team Science Lead, Drug Development


What is Martin Braddock's personal email address?

Martin Braddock's personal email address is m****[email protected]


What is Martin Braddock's business email address?

Martin Braddock's business email address is m****[email protected]


What is Martin Braddock's Phone Number?

Martin Braddock's phone +44 ** **** *188


What industry does Martin Braddock work in?

Martin Braddock works in the Pharmaceuticals industry.


About Martin Braddock

📖 Summary

Broad Pharma drug discovery and science management and leadership to development projects (target identification to phase III). Extensive experience in drug discovery from target identification through to lead optimisation in multiple therapeutic areas. Drug discovery project leader taking 8 compounds to candidate selection for first time in man. Management experience (Discovery Bioscience Department Director, AstraZeneca, delivering biochemistry, pharmacology and translational science supporting selection of 18 small molecule and 4 biological candidate drugs); Disease Sciences Unit Head, GlaxoSmithKline, delivering cellular biology support to 6 small molecule drug candidates). Dual scientific and project leading; 31 years research, development and management experience (including 20 years in Drug Discovery and Development (AstraZeneca and GlaxoSmithKline) & 11 years holding academic positions, 4 years as a Royal Society University Research Fellow at Oxford University with own secured research grant funding). Research experience in – metabolic diseases, cardio-vascular, respiratory and inflammatory/autoimmune disease, HIV and AIDS research, alzheimer's, soft and hard tissue repair and regeneration. Awarded a Royal Society University Research Fellowship. Elected Fellow of the Royal Society of Biology in recognition of contribution to biological sciences. Invited Fellow of the Royal Society of Medicine. Recipient of an Alumnus Achievement Award (University of Salford) for outstanding contribution to science. Elected Fellow of the Royal Astronomical Society Specialties: Small and large molecule drug discovery up to candidate selection, early product support for multiple development projects; line and matrix management (up to 82 people). Accomplished team builder, building and managing establishing networks of academic collaborators and clinical experts. Invited expert reviewer and advisor for multiple international grant awarding bodiesTralokinumab Global Development Team Science Lead, Drug Development @ Tralokinumab is an IL-13 monoclonal antibody in phase III clinical development for patients with severe asthma. My role is to build and strengthen the science throughout the phase III clinical programme, aligned to the target product profile to support both the regulatory submission and the developing brand within the portfolio of late stage development candidates. From November 2013 to Present (2 years 2 months) Senior Principal Scientist Late Stage Development Projects @ Provide delivery of scientific support, through rigorous construction of non-clinical, translational and clinical science build to multiple late stage phase IIb and phase III clinical development projects in Inflammation, Neuroscience and Respiratory Global Medicines Development in AstraZeneca and company subsiduaries. From September 2013 to Present (2 years 4 months) Senior Principal Scientist @ Role includes contributing to the development of scientists in R&D Charnwood, dissemination of AstraZeneca R&D science activities to external groups and bodies involved in science education and chair of the Science Leadership Team comprising scientists from chemistry, bioscience and DMPK from both Lund and Charnwood R&D sites. From June 2004 to Present (11 years 7 months) Fostamatinib Global Development Team Science Lead, Drug Development @ Fostamatinib is a SYK inhibitor licensed by AstraZeneca from Rigel Pharmaceuticals for clinical development in rheumatoid arthritis (RA). The drug has now completed phase III clinical trials. As science lead, I had responsibility for ensuring that evolving science would support regulatory submission. In addition I developed the science plan to build the brand with a large number of external collaborators through both CROs and academic institutes. From January 2010 to December 2013 (4 years) Leader Global Biology Network @ Leader of the Global Biology Network (GBN) across all AstraZeneca research sites. The GBN is reponsible for harmonisation of processes involving bioscience in all aspects of drug discovery from pre-competitive data sharing, target identification and validation through to asset exploitation, candidate drug re-positioning, exploiting value in co-morbid indications and new technology investments. From January 2009 to July 2011 (2 years 7 months) Director, Discovery Bioscience @ Head of Discovery Bioscience with line mangement responsibility for 82 people specialising in lead optimisation drug discovery and translational science for both small molecule and biological projects. Therapeutic areas covered are respiratory (asthma, COPD), autoimmune disease (RA) and OA with a variety of targets including chemokines, cytokines and their cognate receptors, transporters, ion channels and kinases. While managing a budget of $6M, my department supported upto 22 compounds in early and mid-stage clinical development with product support and translational science activities. From March 2006 to December 2008 (2 years 10 months) Global Project Leader - Drug Discovery @ Lead optimisation project leader for a P2X7 receptor antagonist drug discovery project delivering three candidate drugs into clinical development for inflammatory and respiratory disease. Most advanced; AZD9056 reached phase IIb clinical development in rheumatoid arthritis. From March 2001 to June 2008 (7 years 4 months) Associate Director @ Line management responsiility for 18 staff working on lead optimisation drug discovery projects in autoimmune disease. From November 2000 to June 2006 (5 years 8 months) Global Leader Disease Strategy Team - Inflammation @ Chair of a cross-functional global discipline team setting strategic direction for the inflammation research area for projects in discovery and early development. From 2004 to 2006 (2 years) Head Disease Sciences Unit @ Head of Disease Cell Biology managing pre-clinical biology supporting multiple therapeutic areas (CNS - Alzheimer's; Respiratory - Asthma, COPD; Autoimmune disease - Rheumatology; Cardiovascular; Vascular Disease Prevention). From June 1999 to November 2000 (1 year 6 months) Programme Leader, Wound Repair and Tissue Regeneration @ Responsible for discovery and validation of gene therapeutic approaches for promoting tissue repair in skin and bone and for skin anti-fibrotics. From June 1998 to June 2000 (2 years 1 month) Joint Steering Committee Member @ JSC member for a functional genomics strategic intitiative with Nemapharm pharmaceuticals From June 1998 to May 2000 (2 years) Team Leader @ Team Leader in Vascular Diseases Unit responsible for basic research in vascular biology, application of gene therapy to atherosclerosis and understanding and exploitation of fluid shear stress on gene expression in human vasculature. From January 1995 to September 1998 (3 years 9 months) Royal Society Research Fellow @ Research grant holder supporting basic research in HIV biology, specialising in: determination of mechanism of action studies for leading anti-viral compounds at the level of gene expression, transcriptional and translational control of HIV open reading frames, masked message control of gene expression and mRNA sub-cellular localisation of intronic designed transcription units. From June 1991 to January 1995 (3 years 8 months) Post-doctoral Research Fellow @ Post-doc in the lab of Susan and Alan Kingsman working on bovine papilloma virus and HIV molecular biology: transcriptional and translational control of E2, tat and rev open reading frames. From September 1987 to June 1991 (3 years 10 months) Post-doctoral Research Fellow @ Post-doc in the lab of Grahame Hardie and Philip Cohen; MRC Protein Phosphorylation Group, Medical Sciences Institute working on the molecular cloning of mammalian fatty acid synthetase. From June 1984 to September 1987 (3 years 4 months) Ph.D, Radiation Biology @ MRC Radiobiology Unit Harwell, Holt Radium Institute and University of Salford From 1981 to 1984 B.Sc., Biochemistry @ University of Salford From 1978 to 1981 Richard Hale School From 1971 to 1978 Richard Hale School Martin Braddock is skilled in: Drug Discovery, Drug Development, Pharmacology, Clinical Development, Biochemistry, Translational Medicine, Cell Biology, Molecular Biology, Pharmaceutical Industry, Inflammation, Neuroscience, Project Management, CRO, Molecular & Cellular Biology, R&D


Martin Braddock’s Personal Email Address, Business Email, and Phone Number

are curated by ContactOut on this page.

10x your recruitment & sales conversations

Contact over 200M professionals
instantly by email or phone. Reveal
personal & work email addresses, as
well as phone numbers accurately with
our ContactOut Chrome extension.

In a nutshell

Martin Braddock's Personality Type

Extraversion (E), Sensing (S), Feeling (F), Perceiving (P)

Average Tenure

3 year(s), 9 month(s)

Martin Braddock's Willingness to Change Jobs

Unlikely

Likely

Open to opportunity?

There's 91% chance that Martin Braddock is seeking for new opportunities

Martin Braddock's Achievements

Research Fellow

Issued by Hertford College, University of Oxford · January 1990

Research Recognition Award

Issued by Stuart Strange Trust (now Vascilitis UK) · May 1998

Alumnus Achievement Award

Issued by University of Salford · December 2012

Diploma in Astrobiology

Issued by IARC · July 2013

GCSE Astronomy

Issued by Edexel through Starlearner.com · August 2014

Fellow of the Royal Astronomical Society

Issued by Royal Astronomical Society, London · May 2015

University Certificate in Cosmology

Issued by UCLAN (University of Central Lancashire) · July 2015

Engage candidates 10x faster

Enjoy unlimited access and discover candidates outside of LinkedIn

Trusted by 400K users from

76% of Fortune 500 companies

Microsoft Nestle PWC JP Morgan Merck Rackspace WarnerMedia Randstad Yelp Google

The most accurate data ever

CCPA Compliant
GDPA Aligned
150M Personal Emails
300M Work Emails
50M Direct Dials
200M Professional Profiles
30M Company Profiles

Hire Anyone, Anywhere
with ContactOut today

Making remote or global hires? We can help.

  • 50 contacts/month
  • Works on standard LinkedIn only
  • Work emails, personal emails, mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free